Skip to Content

Bendroflumethiazide / nadolol Pregnancy and Breastfeeding Warnings

Bendroflumethiazide / nadolol is also known as: Corzide, Corzide 40/5, Corzide 80/5

Medically reviewed on May 24, 2017

Bendroflumethiazide / nadolol Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies with bendroflumethiazide have not been reported. Animal studies with nadolol have revealed evidence of embryotoxicity and fetotoxicity, but no teratogenicity. In humans, neonates whose mothers received nadolol at parturition exhibited bradycardia, hypoglycemia, and associated symptoms. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Bendroflumethiazide / nadolol Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes (bendroflumethiazide, nadolol)

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Corzide (bendroflumethiazide-nadolol)" Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. Corzide (bendroflumethiazide-nadolol)" Bristol-Myers Squibb, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide